Ticker Symbol: PHVS
Pharvaris NV
$15.75 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Currency:
USD
Asset
Type: Common Stock
CIK:0001830487
Company Profile
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: N/A
Website: pharvaris.com
CEO: N/A
Tags:
N/A
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $18.55
Change:
$0.05
(
0.27%)
Days Range: $18.00 - $18.91
Beta: -
52wk. High: $26.86
52wk. Low: $1.77
Ytd. Change 64.71%
50 Day Moving Average: $19.96
200 Day Moving Average: $14.78
Shares Outstanding: 40856824
Valuation
Market Cap: 75.8B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A